RaySight Medical Secures Nearly RMB 1 Billion Strategic Financing and Files IPO Prospectus

Recently, Shenzhen Raysightmed Co., Ltd. (hereinafter referred to as "RaysightMed") officially announced the completion of a new round of strategic financing amounting to nearly RMB 100 million. This round of financing was jointly invested by Haihe Industry Fund and Zhongli Fund, representing state-owned industrial capital at both municipal and district levels in Tianjin. The project has been officially established in Tianjin, which will comprehensively accelerate the industrial expansion of RaysightMed's full product line and the large-scale promotion of its market in northern China.

RaysightMed will leverage this financing opportunity to deepen its physical industrial presence in Tianjin by establishing standardized production facilities and building a mass-production system for high-end medical devices. Through a dual strategy of production bases and regional marketing centers, the company will comprehensively cover the core healthcare markets in North, Northeast, and Northwest China, completing its national industrialization and distribution network to provide robust capacity and service support for the rapid scale-up of its currently approved products.

This round of financing will focus on advancing the commercial promotion and capacity upgrade of the full product line, with priority given to coronary physiology, non-invasive coronary assessment, and intracardiac echocardiography. The goal is to continuously expand the clinical penetration rate and market share of domestically produced innovative cardiovascular devices.

Zheng Lingxiao, Founder and CEO of RaysightMed, stated that the capital injection from Tianjin state-owned assets and the subsequent industrial localization will provide ample funding and industrial support for the company’s R&D of advanced AI-powered surgical robots and the promotion of its chronic disease health management products. The company will continue to root itself in local clinical needs, refine its series of products for cerebrovascular and cardiovascular diseases, steadily advance product commercialization, and accelerate its growth into a leading global enterprise in intelligent cardiovascular healthcare.